세계의 착상전 유전자 검사(PGT) 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Persistence Market Research has recently published an extensive report on the global Preimplantation Genetic Testing (PGT) Market. This report offers a comprehensive analysis of key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

• Preimplantation Genetic Testing Market Size (2024E): USD 0.68 Bn
• Projected Market Value (2031F): USD 1.48 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 9%

Preimplantation Genetic Testing Market - Report Scope:

The Preimplantation Genetic Testing (PGT) Market covers a range of genetic testing procedures used in fertility treatments, particularly in in-vitro fertilization (IVF) processes. PGT allows for the screening of embryos for genetic disorders, increasing the chances of healthy pregnancies. The market is expanding due to the rising awareness of genetic disorders, advancements in fertility treatments, and the integration of precision health and personalized medicine. PGT finds applications in various settings, including hospitals, fertility clinics, and home use. The growth is driven by increasing infertility rates, delayed childbearing, and technological advancements in genetic testing.

Market Growth Drivers:

Advances in Genetic Technology

Rapid advancements in genetic technology, such as next-generation sequencing (NGS) and CRISPR, are key drivers of the PGT market. These technologies allow for more accurate, efficient, and comprehensive genetic screening, improving the precision of detecting genetic anomalies in embryos. NGS enables the analysis of multiple genes simultaneously, reducing both time and costs associated with genetic testing. The development of non-invasive testing methods is making PGT more accessible and acceptable to prospective parents, driving demand for healthier pregnancies and the prevention of genetic disorders.

Rising Infertility Rates and Delayed Childbearing

Increasing infertility rates and a global trend towards delayed childbearing are contributing significantly to the market's growth. Lifestyle factors, including stress, diet, and environmental pollutants, are leading to higher infertility rates. As more couples opt to have children later in life, the risk of chromosomal abnormalities increases, making PGT a critical tool for selecting healthy embryos and reducing genetic risks. The growing awareness of assisted reproductive technologies (ART) is further boosting demand for PGT, as couples seek to ensure the health and viability of their pregnancies.

Growing Acceptance and Awareness

Increasing awareness of the benefits of genetic testing, along with the decreasing stigma surrounding fertility treatments, is driving market expansion. Educational campaigns, advancements in genetic counseling, and media coverage are raising public awareness, leading to a broader acceptance of PGT. As couples become more informed about the benefits of genetic screening, demand for PGT rises. Insurance companies are also recognizing the benefits of covering PGT, further driving market growth.

Market Restraints:

High Costs and Limited Accessibility

The high costs associated with PGT are a significant restraint on the market. The advanced technologies required for genetic testing make the procedure expensive, limiting its accessibility, particularly in developing countries with limited healthcare infrastructure. The lack of insurance coverage for PGT also limits its accessibility to higher-income individuals. This financial barrier hampers the market's growth potential by restricting access to those who can afford the out-of-pocket expenses.

Ethical and Legal Concerns

Ethical concerns regarding the selection of embryos based on genetic characteristics raise complex questions about eugenics and genetic discrimination. These concerns lead to public apprehension and regulatory challenges, which impact the market's growth. Regulatory environments vary significantly across regions, with some countries imposing strict regulations or bans on genetic testing, further complicating market expansion.

Market Opportunities:

Integration of Personalized Medicine and Precision Health

The integration of personalized medicine presents a significant opportunity for the PGT market. As healthcare increasingly adopts personalized approaches, PGT fits seamlessly into this trend by enabling the selection of genetically healthy embryos. With advancements in genomics and artificial intelligence, PGT is becoming more accurate and accessible, meeting the growing demand for tailored healthcare solutions. The ability to predict genetic risks and customize treatment plans aligns with modern healthcare's focus on precision, creating substantial growth opportunities in the PGT market.

Key Questions Answered in the Report:

• What are the primary factors driving the global Preimplantation Genetic Testing (PGT) Market?
• Which procedures and applications are leading in the PGT market?
• How are technological advancements shaping the competitive landscape?
• Who are the key players in the market, and what strategies are they employing?
• What are the emerging trends and future prospects for the global PGT market?

Competitive Intelligence and Business Strategy:

Key players in the global Preimplantation Genetic Testing Market are focusing on research and development to innovate and enhance their product offerings. Companies are investing in advanced technologies like AI for genetic analysis, making PGT more efficient and accessible. Collaborations with fertility clinics and hospitals are strengthening their market presence. Emphasis on consumer education and marketing strategies fosters growth and brand loyalty in the evolving PGT market landscape.

Key Market Players

• Quest Diagnostics Incorporated
• Natera, Inc.
• COOPER SURGICAL, INC.
• Genea Pty Limited.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Bioarray S.L.
• Illumina, Inc.
• Igenomix
• RGI
• F. Hoffmann-La Roche Ltd.

Market Segmentation

By Procedure

• Genetic Diagnosis
• Genetic Screening

By Product

• Reagents
• Instruments

By Technology

• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)

By Region

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• The Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Preimplantation Genetic Testing Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Epidemiology - Disease Prevalence and Incidence
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
• 4.3. Global Preimplantation Genetic Testing Market Outlook: Test Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 4.3.3.1. Diagnostics
    • 4.3.3.2. Screening
• 4.4. Market Attractiveness Analysis: Test Type
• 4.5. Global Preimplantation Genetic Testing Market Outlook: Technology
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 4.5.3.1. CGH-based
    • 4.5.3.2. FISH-based
    • 4.5.3.3. NGS-based
    • 4.5.3.4. SNP-based
    • 4.5.3.5. PCR-based
• 4.6. Market Attractiveness Analysis: Technology
• 4.7. Global Preimplantation Genetic Testing Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 4.7.3.1. Infectious Diseases
    • 4.7.3.2. Neurological Diseases
    • 4.7.3.3. Autoimmune Diseases
    • 4.7.3.4. Oncology
    • 4.7.3.5. Others
• 4.8. Market Attractiveness Analysis: End User

5. Global Preimplantation Genetic Testing Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Test Type
  • 6.2.3. By Technology
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
  • 6.4.1. Diagnostics
  • 6.4.2. Screening
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
  • 6.5.1. CGH-based
  • 6.5.2. FISH-based
  • 6.5.3. NGS-based
  • 6.5.4. SNP-based
  • 6.5.5. PCR-based
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
  • 6.6.1. Hospitals
  • 6.6.2. Diagnostic Labs
  • 6.6.3. Research & Academic Institutions
  • 6.6.4. Specialized Clinics
  • 6.6.5. Others
• 6.7. Market Attractiveness Analysis

7. Europe Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Test Type
  • 7.2.3. By Technology
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
  • 7.4.1. Diagnostics
  • 7.4.2. Screening
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
  • 7.5.1. CGH-based
  • 7.5.2. FISH-based
  • 7.5.3. NGS-based
  • 7.5.4. SNP-based
  • 7.5.5. PCR-based
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
  • 7.6.1. Hospitals
  • 7.6.2. Diagnostic Labs
  • 7.6.3. Research & Academic Institutions
  • 7.6.4. Specialized Clinics
  • 7.6.5. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Test Type
  • 8.2.3. By Technology
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
  • 8.4.1. Diagnostics
  • 8.4.2. Screening
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
  • 8.5.1. CGH-based
  • 8.5.2. FISH-based
  • 8.5.3. NGS-based
  • 8.5.4. SNP-based
  • 8.5.5. PCR-based
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
  • 8.6.1. Hospitals
  • 8.6.2. Diagnostic Labs
  • 8.6.3. Research & Academic Institutions
  • 8.6.4. Specialized Clinics
  • 8.6.5. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Test Type
  • 9.2.3. By Technology
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
  • 9.4.1. Diagnostics
  • 9.4.2. Screening
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
  • 9.5.1. CGH-based
  • 9.5.2. FISH-based
  • 9.5.3. NGS-based
  • 9.5.4. SNP-based
  • 9.5.5. PCR-based
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
  • 9.6.1. Hospitals
  • 9.6.2. Diagnostic Labs
  • 9.6.3. Research & Academic Institutions
  • 9.6.4. Specialized Clinics
  • 9.6.5. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Test Type
  • 10.2.3. By Technology
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
  • 10.4.1. Diagnostics
  • 10.4.2. Screening
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
  • 10.5.1. CGH-based
  • 10.5.2. FISH-based
  • 10.5.3. NGS-based
  • 10.5.4. SNP-based
  • 10.5.5. PCR-based
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
  • 10.6.1. Hospitals
  • 10.6.2. Diagnostic Labs
  • 10.6.3. Research & Academic Institutions
  • 10.6.4. Specialized Clinics
  • 10.6.5. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Test Type
  • 11.2.3. By Technology
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
  • 11.4.1. Diagnostics
  • 11.4.2. Screening
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
  • 11.5.1. CGH-based
  • 11.5.2. FISH-based
  • 11.5.3. NGS-based
  • 11.5.4. SNP-based
  • 11.5.5. PCR-based
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
  • 11.6.1. Hospitals
  • 11.6.2. Diagnostic Labs
  • 11.6.3. Research & Academic Institutions
  • 11.6.4. Specialized Clinics
  • 11.6.5. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Agilent Technologies Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Abbott Laboratories
  • 12.3.3. CooperSurgical Inc.
  • 12.3.4. Oxford Gene Technology IP
  • 12.3.5. Illumina Inc.
  • 12.3.6. Thermo Fisher Scientific Inc.
  • 12.3.7. PerkinElmer Inc.
  • 12.3.8. Genea Limited
  • 12.3.9. Natera Inc.
  • 12.3.10. Rubicon Genomics Inc.
  • 12.3.11. CombiMatrix Corporation

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations